---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-027121"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2022-09-29T23:59:59+00:00"
generated_at: "2026-06-23T06:51:09.328964+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Anixa Biosciences reports favorable safety and stable tumor lesions in first patient of CAR-T trial

## Summary
- First patient treated in chimeric endocrine receptor T-cell (CAR-T) clinical trial shows favorable safety signals.
- Imaging at one month post-treatment indicates tumor lesions are stable and not growing.
- Patient appears to be doing well and will continue to be monitored; enrollment continues.
- Data presented by inventor Dr. Jose Conejo-Garcia at AACR/Rivkin Ovarian Cancer Symposium.

## SEC filing metadata
- accession: 0001493152-22-027121
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2022-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315222027121/0001493152-22-027121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315222027121/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-027121
- JSON: https://secwatch.observer/filing/0001493152-22-027121.json
- Plain text: https://secwatch.observer/filing/0001493152-22-027121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.